Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS

Key Points

• Enanta Pharmaceuticals reported a quarterly loss of $0.67 per share, missing the analyst consensus estimate of a $0.51 loss by $0.16. The company also posted negative return on equity of 64.04% and a negative net margin of 89.56%.
• Shares rose 0.3% to $13.81 during Monday trading. Institutional investors and hedge funds own approximately 94.99% of the company’s stock.
• Analyst sentiment remains mixed but leans positive, with seven Buy ratings and one Sell rating. Enanta has a consensus rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.16), Zacks reports. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.

Enanta Pharmaceuticals Stock Up 0.3%

ENTA traded up $0.04 during midday trading on Monday, hitting $13.81. 78,940 shares of the company were exchanged, compared to its average volume of 195,215. The firm's 50 day moving average price is $13.08 and its 200-day moving average price is $13.42. Enanta Pharmaceuticals has a 1-year low of $6.45 and a 1-year high of $17.15. The firm has a market capitalization of $401.65 million, a P/E ratio of -5.33 and a beta of 0.98.

Institutional Trading of Enanta Pharmaceuticals

A number of large investors have recently bought and sold shares of ENTA. Deutsche Bank AG increased its holdings in Enanta Pharmaceuticals by 4.6% during the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company's stock worth $380,000 after buying an additional 1,055 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company's stock valued at $173,000 after purchasing an additional 1,100 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company's stock worth $216,000 after buying an additional 1,383 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in Enanta Pharmaceuticals by 13.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company's stock valued at $197,000 after purchasing an additional 1,940 shares during the period. Finally, Meeder Asset Management Inc. bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at $32,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ENTA has been the subject of several analyst reports. Wall Street Zen cut Enanta Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday, May 31st. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Enanta Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $20.29.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source